(Press-News.org) The concept behind gene therapy is simple: deliver a healthy gene to compensate for one that is mutated. New research published today in the Journal of Neuroscience suggests this approach may eventually be a feasible option to treat Rett Syndrome, the most disabling of the autism spectrum disorders. Gail Mandel, Ph.D., a Howard Hughes Investigator at Oregon Health and Sciences University, led the study. The Rett Syndrome Research Trust, with generous support from the Rett Syndrome Research Trust UK and Rett Syndrome Research & Treatment Foundation, funded this work through the MECP2 Consortium.
In 2007, co-author Adrian Bird, Ph.D., at the University of Edinburgh astonished the scientific community with proof-of-concept that Rett is curable, by reversing symptoms in adult mice. His unexpected results catalyzed labs around the world to pursue a multitude of strategies to extend the pre-clinical findings to people.
Today's study is the first to show reversal of symptoms in fully symptomatic mice using techniques of gene therapy that have potential for clinical application.
Rett Syndrome is an X-linked neurological disorder primarily affecting girls; in the US, about 1 in 10,000 children a year are born with Rett. In most cases symptoms begin to manifest between 6 and 18 months of age, as developmental milestones are missed or lost. The regression that follows is characterized by loss of speech, mobility, and functional hand use, which is often replaced by Rett's signature gesture: hand-wringing, sometimes so intense that it is a constant during every waking hour. Other symptoms include seizures, tremors, orthopedic and digestive problems, disordered breathing and other autonomic impairments, sensory issues and anxiety. Most children live into adulthood and require round-the-clock care.
The cause of Rett Syndrome's terrible constellation of symptoms lies in mutations of an X-linked gene called MECP2 (methyl CpG-binding protein). MECP2 is a master gene that regulates the activity of many other genes, switching them on or off.
"Gene therapy is well suited for this disorder," Dr. Mandel explains. "Because MECP2 binds to DNA throughout the genome, there is no single gene currently that we can point to and target with a drug. Therefore the best chance of having a major impact on the disorder is to correct the underlying defect in as many cells throughout the body as possible. Gene therapy allows us to do that."
Healthy genes can be delivered into cells aboard a virus, which acts as a Trojan horse. Many different types of these Trojan horses exist. Dr. Mandel used adeno-associated virus serotype 9 (AAV9), which has the unusual and attractive ability to cross the blood-brain barrier. This allows the virus and its cargo to be administered intravenously, instead of employing more invasive direct brain delivery systems that require drilling burr holes into the skull.
Because the virus has limited cargo space, it cannot carry the entire MECP2 gene. Co-author Brian Kaspar of Nationwide Children's Hospital collaborated with the Mandel lab to package only the gene's most critical segments. After being injected into the Rett mice, the virus made its way to cells throughout the body and brain, distributing the modified gene, which then started to produce the MeCP2 protein.
As in human females with Rett Syndrome, only approximately 50% of the mouse cells have a healthy copy of MECP2. After the gene therapy treatment 65% of cells now had a functioning MECP2 gene.
The treated mice showed profound improvements in motor function, tremors, seizures and hind limb clasping. At the cellular level the smaller body size of neurons seen in mutant cells was restored to normal. Biochemical experiments proved that the gene had found its way into the nuclei of cells and was functioning as expected, binding to DNA.
One Rett symptom that was not ameliorated was abnormal respiration. Researchers hypothesize that correcting this may require targeting a greater number of cells than the 15% that had been achieved in the brainstem.
"We learned a critical and encouraging point with these experiments – that we don't have to correct every cell in order to reverse symptoms. Going from 50% to 65% of the cells having a functioning gene resulted in significant improvements," said co-author Saurabh Garg.
One of the potential challenges of gene therapy in Rett is the possibility of delivering multiple copies of the gene to a cell. We know from the MECP2 Duplication Syndrome that too much of this protein is detrimental. "Our results show that after gene therapy treatment the correct amount of MeCP2 protein was being expressed. At least in our hands, with these methods, overexpression of MeCP2 was not an issue," said co-author Daniel Lioy.
Dr. Mandel cautioned that key steps remain before clinical trials can begin. "Our study is an important first step in highlighting the potential for AAV9 to treating the neurological symptoms in Rett. We are now working on improving the packaging of MeCP2 in the virus to see if we can target a larger percentage of cells and therefore improve symptoms even further," said Mandel. Collaborators Hélène Cheval and Adrian Bird see this as a promising follow up to the 2007 work showing symptom reversal in Rett mice. "That study used genetic tricks that could not be directly applicable to humans, but the AAV9 vector used here could in principle deliver a gene therapeutically. This is an important step forward, but there is a way to go yet."
"Gene therapy has had a tumultuous road in the past few decades but is undergoing a renaissance due to recent technological advances. Europe and Asia have gene therapy treatments already in the clinic and it's likely that the US will follow suit. Our goal now is to prioritize the next key experiments and facilitate their execution as quickly as possible. Gene therapy, especially to the brain, is a tricky undertaking but I'm cautiously optimistic that with the right team we can lay out a plan for clinical development. I congratulate the Mandel and Bird labs on today's publication, which is the third to be generated from the MECP2 Consortium in a short period of time," said Monica Coenraads, Executive Director of the Rett Syndrome Research Trust and mother of a teenaged daughter with the disorder.
INFORMATION:
Publication Title: Systemic delivery of MeCP2 rescues behavioral and cellular deficits in female mouse models of Rett syndrome.
About the Rett Syndrome Research Trust
The Rett Syndrome Research Trust is a non-profit exclusively devoted to global research on Rett Syndrome and related MECP2 disorders. Our goal is to heal children and adults who will otherwise suffer the effects of these disorders for the rest of their lives. To learn more about the Trust, please visit http://www.ReverseRett.org
Our partners in supporting this work are parents' organizations worldwide including RSRT UK, Rett Syndrome Research & Treatment Foundation (Israel), Stichting Rett Syndrome (Holland), Rett Syndrom Deutschland e.V., Skye Wellesley Foundation (UK) and American organizations, The Kate Foundation for Rett Syndrome Research, Girl Power 2 Cure, Eva Fini Fund at RSRT, Rocky Mountain Rett Association and the New Jersey Rett Syndrome Association.
About the MECP2 Consortium
The MECP2 Consortium, launched by the Rett Syndrome Research Trust in 2011 with a $1 million lead gift by Trustee Tony Schoener and his wife Kathy, fosters novel alliances among leading scientists to interrogate the molecules at the root of Rett Syndrome. Consortium members include Adrian Bird of the University of Edinburgh, Michael Greenberg of Harvard University and Gail Mandel of Oregon Health and Sciences University.
First pre-clinical gene therapy study to reverse Rett symptoms
2013-08-21
ELSE PRESS RELEASES FROM THIS DATE:
Honeyguide birds destroy own species' eggs to eliminate competition
2013-08-21
Like cuckoos, honeyguides are parasitic birds that lay their eggs in other birds' nests and dupe them into raising their young. Now scientists reveal that, unlike in cuckoos, the resemblance between honeyguide eggs and those of their bee-eater bird hosts hasn't evolved to trick hosts into accepting the imposter egg as one of their own. Rather, it appears to have evolved to trick other honeyguides who would otherwise destroy the eggs because of fierce competition for host nests. The new research is published today, 21 August, in the journal Biology Letters.
Honeyguides ...
Study implicates dopamine in food restriction, drug abuse
2013-08-21
SAN ANTONIO (Aug. 20, 2013) — Scientists today reported a possible basis for why food-restricted animals show increased susceptibility to drugs of abuse. This association has puzzled researchers since it was first observed more than three decades ago.
Senior author Michael Beckstead, Ph.D., from the School of Medicine at The University of Texas Health Science Center San Antonio, said the team found that dopamine neurons in a brain region called the substantia nigra fire bursts more than twice as frequently in chronically food-restricted mice. Cocaine significantly enhanced ...
Social giving makes us happier
2013-08-21
People usually feel good when they make a charitable donation, but they feel even better if they make the donation directly to someone they know or in a way that builds social connection. Research to be published in the International Journal of Happiness and Development investigates for the first time how social connection helps turn generous behavior into positive feelings on the part of the donor.
Lara Aknin of Simon Fraser University, in Burnaby, British Columbia, Canada, and colleagues at the University of British Columbia, Vancouver and Harvard Business School, Massachusetts, ...
3D graphene: Solar cells' new platinum?
2013-08-21
One of the most promising types of solar cells has a few drawbacks. A scientist at Michigan Technological University may have overcome one of them.
Dye-sensitized solar cells are thin, flexible, easy to make and very good at turning sunshine into electricity. However, a key ingredient is one of the most expensive metals on the planet: platinum. While only small amounts are needed, at $1,500 an ounce, the cost of the silvery metal is still significant.
Yun Hang Hu, the Charles and Caroll McArthur Professor of Materials Science and Engineering, has developed a new, inexpensive ...
Epic ocean voyages of coral larvae revealed
2013-08-21
MIAMI – August 20, 2013 -- A new computer simulation conducted at the University of Bristol (UB) and University of Miami (UM) Rosenstiel School of Marine & Atmospheric Science has revealed the epic, ocean-spanning journeys travelled by millimetre-sized coral larvae through the world's seas.
The study, published in Global Ecology and Biogeography, is the first to recreate the oceanic paths along which corals disperse globally, and will eventually aid predictions of how coral reef distributions may shift with climate change.
Coral reefs are under increasing threat ...
Multiple genes manage how people taste sweeteners
2013-08-21
Genetics may play a role in how people's taste receptors send signals, leading to a wide spectrum of taste preferences, according to Penn State food scientists. These varied, genetically influenced responses may mean that food and drink companies will need a range of artificial sweeteners to accommodate different consumer tastes.
"Genetic differences lead to differences in how people respond to tastes of foods," said John Hayes, assistant professor, food science and director of the sensory evaluation center.
Based on the participants' genetic profile, researchers were ...
Chromosome 21 abnormality tells oncologists to treat pediatric ALL more aggressively
2013-08-21
A recent study by members of the Children's Oncology Group reports results of a large trial showing that children whose leukemia cells have amplification of a portion of chromosome 21 may require more aggressive treatment for Acute Lymphoblastic Leukemia (ALL) than children without this gene amplification.
"This helps identify patients who need more therapy than they may otherwise get," says Stephen Hunger, MD, investigator at the University of Colorado Cancer Center, professor of pediatrics at the University of Colorado School of Medicine, and director of the Center ...
Redesign for sudden autopilot disconnection needed, say flight safety experts
2013-08-21
Flight safety experts studying recent high-profile plane crashes found sudden autopilot disconnection to be a design flaw that creates unnecessary emergencies by surprising pilots during critical, high-workload episodes.
"The sudden disengagement of autopilot is analogous to a pilot suddenly throwing up his or her hands and blurting to the copilot, 'Your Plane!'" says Eric E. Geiselman, lead author of a recently published two-article Ergonomics in Design series, "Flight Deck Automation: Invaluable Collaborator or Insidious Enabler" (July issue) and "A Call for Context-Aware ...
New explanation for key step in anthrax infection proposed by NIST and USAMRIID
2013-08-21
A new hypothesis concerning a crucial step in the anthrax infection process has been advanced by scientists at the National Institute of Standards and Technology (NIST) and the U.S. Army Medical Research Institute for Infectious Diseases (USAMRIID) at Fort Detrick, Md.
The research teams have explored the behavior of the toxins that rapidly overwhelm the body as the often-fatal disease progresses. Their findings suggest a new possible mechanism by which anthrax bacteria deliver the protein molecules that poison victims. Anthrax is easily weaponized; the findings could ...
NIST study advances use of iris images as a long-term form of identification
2013-08-21
A new report* by biometric researchers at the National Institute of Standards and Technology (NIST) uses data from thousands of frequent travelers enrolled in an iris recognition program to determine that no consistent change occurs in the distinguishing texture of their irises for at least a decade. These findings inform identity program administrators on how often iris images need to be recaptured to maintain accuracy.
For decades, researchers seeking biometric identifiers other than fingerprints believed that irises were a strong biometric because their one-of-a-kind ...